The Independent Assessment Committee is responsible for determining the eligibility of a vaccine for the Advance Market Commitment
The Independent Assessment Committee (IAC) was created as an impartial oversight body of the AMC. The IAC is responsible for determining whether a candidate vaccine meets the minimally acceptable profile (the “Target Product Profile”) in terms of vaccine serotypes, target population/target age group, dosage schedule, route of administration and product formulation. The Target Product Profile is designed to ensure that AMC vaccines meet developing country needs.
In its monitoring role, the IAC appraises information and endorses annual progress reports. In addition, the IAC establishes when and if an adjustment of the pre-set long-term price of vaccines is necessary. Finally, the IAC has a dispute resolution function.
The IAC Selection and Oversight Panel, a group of international experts, is charged with the task of selecting and appointing IAC members as well as with reviewing claims of potential or declared conflicts of interest involving IAC members.
The composition of the IAC, in terms of required areas of expertise, was decided upon by the AMC stakeholders during the design phase. The IAC membership reflects a balance of significant expertise in the following areas: public health, health economics, vaccine business development, vaccine industry economics, contract law, public-private finance and clinical performance and delivery systems.
As per the IAC Bylaws, the IAC Selection and Oversight Panel was asked to select the IAC Chairperson and Vice Chairperson. The selection was decided on 6th July 2009 and announced to all IAC members on 14th July 2009. Claire Broome and Soonman Kwon were selected as the Chairperson and Vice Chairperson respectively of the Independent Assessment Committee (IAC).